Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 535-546

  Watts, M J ^a   Sullivan, A M ^a   Jamieson, E ^a   Pearce, R ^a   Fielding, A ^a   Devereux, S ^a   Goldstone, A H ^a   Linch, D C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADOLESCENT; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL PROTOCOL; COLONY FORMING CELL; FEMALE; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE TRANSFUSION;

EID: 0031024323     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.535     Document Type: Article

References (33)

1. Chopra R, McMillan AK, Linch DC, et al.: The place of high dose BEAM therapy and ABMT in poor prognosis Hodgkin's disease. A single center eight year study of 155 patients. Blood 81:1137-1145, 1993
2. Mills W, Chopra R, McMillan A, et al.: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13:588-595, 1995
3. Tura S, Zinzani PL, Mazza P, et al.: ABMT vs DHAP in residual disease following third generation regimens for aggressive NHL. Blood 80:619, 1992 (suppl 1, abstr)
4. Philip T, Gugliema C, Chauvin F, et al.: Autologous bone marrow transplantation (ABMT) versus conventional chemotherapy (DHAP) in relapsed non-Hodgkin's lymphoma: Final analysis of the Parma randomised study (216 patients). Proc Am Soc Clin Oncol 14:390, 1995 (abstr)
5. Linch DC, Winfield D, Goldstone AH, et al.: Dose intensification with autologous bone marrow transplantation is effective in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 341:138-142, 1993
6. Gianni AM, Bregni M, Siena S, et al.: Rapid and complete haematological reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol 7:139-148, 1989
7. Sheridan WP, Begley CG, Juttner CA, et al.: Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1:640-644, 1992
8. Jones HM, Jones SA, Watts MJ, et al.: Development of a simplified single apheresis approach for peripheral blood progenitor cell transplantation in previously treated patients with lymphoma. J Clin Oncol 12:1693-1702, 1994
9. Beyer J, Schwella N, Zingsem J, et al.: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335, 1995
10. Schmidt N, Linch DC, Dreger P, et al.: Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplant versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353-357, 1996
11. Demirer T, Besinger WI: Optimization of peripheral blood stem cell collection. Curr Opin Haematol 2:219-226, 1995
12. Pettengell R, Morganstern GR, Woll PJ, et al.: Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 82:3770-3777, 1993
13. Dreger P, Marquardt P, Haferlach T, et al.: Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: Timing of harvesting and composition of the leukapheresis product. Br J Cancer 68:950-957, 1993
14. 2 in patients with advanced cancer. Aust NZ J Med 22:660-664, 1992
15. Rosenfeld CS, Shadduck RK, Zeigler ZR, et al.: Cyclophosphamide-mobilized peripheral blood stem cells in patient with lymphoid malignancies. Bone Marrow Transplant 15:433-438, 1995
16. Watts MJ, Jones HM, Sullivan AM, et al.: Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Haematol 91:767-772, 1995
17. Dyson PG, Ho JQ, Dowse TL, et al.: The use of the APAAP technique as a rapid indicator of peripheral blood progenitor levels. Pathology 26:296-300, 1994
18. Khwaja A, Mills W, Leveridge K, et al.: Efficacy of delayed G-CSF after autologous bone marrow transplantation. Bone Marrow Transplant 11:479-482, 1993
19. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
20. + cell purification of peripheral blood stem cell harvests: Experience of 40 immunoaffinity column procedures. Br J Haematol 93:12, 1996 (suppl 1, abstr 46)
21. Gianni-AM, Bregni-M, Siena-S, et al.: Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologie toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 8:768-78, 1990
22. Craig JI, Anthony RS, Stewart EB, et al.: Peripheral blood stem cell mobilisation using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol 85:210-212, 1993
23. Haas R, Mohle R, Fruhauf S, et al.: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787-3794, 1994
24. Schwartzberg L, Birch R, Blanco R, et al.: Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose chemotherapy. Bone Marrow Transplant 11:369-374, 1993
25. Zimmerman TM, Lee WJ, Bender JG, et al.: Quantitative CD34 analysis may be used to guide peripheral blood stem cell harvests. Bone Marrow Transplant 15:439-444, 1995
26. Besinger W, Appelbaum F, Rowley S, et al.: Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547-2555, 1995
27. Linch DC, Milligan DW, Winfield DA, et al.: G-CSF significantly accelerates neutrophil recovery after peripheral blood stem cell transplantation (PBSCT) in lymphoma patients and shortens the time in hospital: Preliminary results of a BNLI randomised trial. Blood 86:221a, 1995 (suppl 1, abstr 873)
28. Klumpp TR, Mangan KF, Goldberg ES, et al.: Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral blood stem cell transplantation: A prospective, randomized trial. J Clin Oncol 13:1323-1327, 1995
29. Boiron JM, Marit G, Faberes C, et al.: Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 12:49-55, 1995
30. Zeller W, Gutensohn K, Stockschlader M, et al.: Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma and cancer of the testis. Bone Marrow Transplant 17:709-713, 1996
31. Hoglund M, Bengtsson M, Simonsson B, et al.: Leukopheresis with peripheral blood progenitor cell (PBPC) harvest in healthy volunteers receiving different doses of lenograstim - Evidence of a dose response effect. Blood 84:1377, 1994 (suppl 1, abstr)
32. Kotasek D, Shepherd KM, Sage RE, et al.: Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 9:11-17, 1992
33. Passos-Coelho JL, Braine HG, Davis JM, et al.: Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 13:705-714, 1995